{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-23-000074","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.001857+00:00","generated_at":"2026-06-20T17:31:14.881623+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Standard BioTools Q4 core revenue $26-27M, seq growth 4-9%; restructuring on track","bullets":["Preliminary Q4 core revenue $26-27M (4-9% sequential growth); FY 2022 ~$94-95M.","Restructuring reduces opex >$30M (20%+); headcount cut 15%, real estate 25%.","Targets positive free cash flow by Q4 2024; year-end cash $165M.","Non-GAAP gross margin goal 65-68% by end of 2023; GAAP 52-55%.","Appointed Betsy Jensen CHRO; Hyperion XTi imaging system on track with 2 early units shipped."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-23-000074","json":"https://secwatch.observer/filing/0000950142-23-000074.json","markdown":"https://secwatch.observer/filing/0000950142-23-000074.md","text":"https://secwatch.observer/filing/0000950142-23-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/0000950142-23-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/eh230318897_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:31:14.881623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"207d53dfeb296d33dae1b9f3524606a809839c96","claim":"STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue in the range of approximately $94 million–$95 million. Guidance reaffirmed.","evidence_excerpt":"For the full year, core product and service revenues are expected to be in the range of approximately $94 million–$95 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/0000950142-23-000074-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"in the range of approximately $94 million–$95 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"941425394e75444d01490aadc7a4c203b21e3a85","claim":"STANDARD BIOTOOLS INC. reported the fourth quarter ended December 31, 2022 results: revenue in the range of $26 million–$27 million. Guidance reaffirmed.","evidence_excerpt":"For the fourth quarter, core product and service revenues (Genomics and Proteomics excluding discontinued and COVID-19 related products) are expected to be in the range of $26 million–$27 million, representing approximately 4%–9% sequential quarterly growth.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000095014223000074/0000950142-23-000074-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"in the range of $26 million–$27 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}